Wpływ montelukastu sodu na czynność płuc i objawy kliniczne u chorych na mukowiscydozę

Inflammatory process contributes to progressive lung tissue damage in cystic fibrosis(CF). Cysteinyl leukotrienes have been found in the sputum of CF patients at concentrations sufficienttocausepotentbiologicaleffect. This study was designed to assess the effect of anti-inflammatory treatment with montelukast sodium in CF patients. Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean&plusmn;SD,54,6 &plusmn; 22,6 before and 62 &plusmn; 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 &plusmn; 23,0 before and 37,5 &plusmn; 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF